Commit To Buy Celldex Therapeutics At $3, Earn 23.3% Using Options

Investors considering a purchase of Celldex Therapeutics, Inc. ( CLDX) shares, but cautious about paying the going market price of $4.17/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the January 2018 put at the $3 strike, which has a bid at the time of this writing of 70 cents. Collecting that bid as the premium represents a 23.3% return against the $3 commitment, or a 20.4% annualized rate of return (at Stock Options Channel we call this the YieldBoost).

Top YieldBoost Puts of the S&P 500 »

Selling a put does not give an investor access to CLDX's upside potential the way owning shares would, because the put seller only ends up owning shares in the scenario where the contract is exercised. And the person on the other side of the contract would only benefit from exercising at the $3 strike if doing so produced a better outcome than selling at the going market price. ( Do options carry counterparty risk? This and six other common options myths debunked). So unless Celldex Therapeutics, Inc. sees its shares fall 28.1% and the contract is exercised (resulting in a cost basis of $2.30 per share before broker commissions, subtracting the 70 cents from $3), the only upside to the put seller is from collecting that premium for the 20.4% annualized rate of return.

Below is a chart showing the trailing twelve month trading history for Celldex Therapeutics, Inc., and highlighting in green where the $3 strike is located relative to that history:

If you liked this article you might like

What Adam Feuerstein Got Right and Wrong About Biotech Stocks in 2016

2016 Was a Terrible Year for Biotech but the Tweets Were on Point

Corbus Pharma Bear Thesis Is Alive and Well on Sclerosis Drug Data Skewed Positive

Celldex Therapeutics (CLDX) Stock Up on Q2 Results

Celldex Therapeutics (CLDX) Is Strong On High Volume Today